AbbVie (ABBV) Cash & Equivalents Growth (3y) (2015 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash & Equiv. Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
14.21% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
4.20% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
11.85% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-18.13% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-27.48% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
15.61% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-7.70% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
2.10% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
1.15% |
| Date | Value |
|---|
| Mar 31, 2026 |
11.85% |
| Dec 31, 2025 |
-17.17% |
| Sep 30, 2025 |
-21.93% |
| Jun 30, 2025 |
-8.78% |
| Mar 31, 2025 |
-5.32% |
| Dec 31, 2024 |
-17.24% |
| Sep 30, 2024 |
-15.86% |
| Jun 30, 2024 |
15.39% |
| Mar 31, 2024 |
22.81% |
| Dec 31, 2023 |
14.89% |
| Sep 30, 2023 |
18.97% |
| Jun 30, 2023 |
13.33% |
| Mar 31, 2023 |
-45.36% |
| Dec 31, 2022 |
-38.69% |
| Sep 30, 2022 |
3.58% |
| Jun 30, 2022 |
18.11% |
| Mar 31, 2022 |
7.59% |
| Dec 31, 2021 |
10.17% |
| Sep 30, 2021 |
14.98% |
| Jun 30, 2021 |
34.06% |
| Mar 31, 2021 |
2.69% |
| Dec 31, 2020 |
-3.16% |
| Sep 30, 2020 |
-2.24% |
| Jun 30, 2020 |
-0.39% |
| Mar 31, 2020 |
105.51% |
| Dec 31, 2019 |
98.56% |
| Sep 30, 2019 |
19.64% |
| Jun 30, 2019 |
-6.50% |
| Mar 31, 2019 |
-13.46% |
| Dec 31, 2018 |
-4.61% |
| Sep 30, 2018 |
-4.57% |
| Jun 30, 2018 |
-21.74% |
| Mar 31, 2018 |
4.44% |
| Dec 31, 2017 |
3.68% |
| Sep 30, 2017 |
3.05% |
| Jun 30, 2017 |
-12.49% |
| Mar 31, 2017 |
-16.49% |
| Dec 31, 2016 |
-19.00% |
| Sep 30, 2016 |
-11.51% |
| Jun 30, 2016 |
-10.22% |
| Mar 31, 2016 |
2.68% |
| Dec 31, 2015 |
12.49% |
| Sep 30, 2015 |
49.49% |
| Jun 30, 2015 |
364.16% |
| Mar 31, 2015 |
477.73% |
